Scholar Rock price target raised to $50 from $45 at BMO Capital

BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $50 from $45 and keeps an Outperform rating on the shares. With Novo’s Catalent site still requiring a reinspection before apitegromab can be approved, management has moved to accelerate tech transfer of commercial capacity for a second fill finish facility, the firm notes. Novo continues to project confidence in a successful year-end reinspection, but BMO believes Scholar Rock’s prudent second facility preparations are likely to improve confidence in a 2026 approval of apitegromab. Non-dilutive financing also provides more stability for Scholar Rock as they continue to wait for their first commercial approval, the firm adds.